| Literature DB >> 29334967 |
Xuhua Shi1, Yongfeng Zhang1, Yuewu Lu2.
Abstract
OBJECTIVES: To investigate the risk factors and treatment strategies for pneumothorax secondary to granulomatosis with polyangiitis (GPA).Entities:
Keywords: Granulomatosis with Polyangiitis; Pneumothorax; Wegener’s granulomatosis
Mesh:
Substances:
Year: 2018 PMID: 29334967 PMCID: PMC5769317 DOI: 10.1186/s13019-018-0695-8
Source DB: PubMed Journal: J Cardiothorac Surg ISSN: 1749-8090 Impact factor: 1.637
Fig. 1The microscopic features of pulmonary nodule obtained by percutaneous lung biopsy in a patient with granulomatous vasculitis (GPA). There are more infiltrating lymphocytes, neutrophils and eosinophils in fibrous tissues. Granulomas composed of tissue cells and inflammatory cells are also visible. There are prominent inflammatory cell infiltration and granuloma in the wall of small vessels. HE staining, 100×
General characteristics of patients with pneumothorax secondary to GPA
| Clinical features | Results |
|---|---|
| Male/Female (case) | 18(72%)/7(28%) |
| Age(year) | 44 ± 15.7(16~70) |
| Duration (weeks) | 26 ± 51.0(0.83~216) |
| Pneumothorax type (case) | |
| Pneumothorax | 11(44%) |
| hydropneumothorax | 5 (20) |
| empyemaa | 8 (32%) |
| Hemopneumothorax | 1 (4%) |
| Chest Imaging(n) | |
| Nodules (Multi/Single) | 22(88%) |
| Cavity | 21(84%) |
| Pulmonary hemorrhage | 1 (4%) |
| Extrapulmonary manifestations (n) | |
| Fever | 11(44%) |
| Skin lesions (purpura, gangrene, ulcers, etc.) | 7 (28%) |
| Nasal and sinus involvement | 15(60%) |
| Oral ulcers | 5 (20%) |
| Glomerulonephritis and other | 13(52%) |
| Nervous system (facial paralysis, mononeuropathy, etc.) | 6 (24%) |
| Arthralgia/arthritis | 11(44%) |
| Parotid swelling | 2 (8%) |
| Laboratory tests | |
| ANCA-positive(n) | 13/20(65%) |
| Anti-PR3(RU/ml) | 176 ± 145.3(26~411) |
| ESR (mm/h) | 92 ± 31.6(24~145) |
| CRP (mg/dl) | 20 ± 27.4(2.35–90) |
| Pleural drainage(n) | 16 |
| Surgery(n) | 7 (28%) |
| Spontaneous absorption(n) | 4 (16%) |
| Death | 10(40%) |
Note: ANCA, anti-neutrophil cytoplasmic antibodies; anti-PR3, anti-proteinase 3 antibody; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein
aThese cases with empyema showed a clear pneumothorax at chest X-ray or CT scan
Infection in patients with pneumothorax secondary to GPA
| The site of infection and pathogens | |
|---|---|
| The site of infection | |
| Lung | 4 (20%) |
| Pleural | 9 (45%) |
| Blood | 3 (15%) |
| Parotid | 1 (5%) |
| Pathogens | |
| Pseudomonas aeruginosa | 5 (25%) |
| Hemolytic streptococcus | 2 (10%) |
| Proteus | 1 (5%) |
| | 1 (5%) |
| Streptococcus faecalis | 1 (5%) |
| | 1 (5%) |
| Aspergillus niger | 1 (5%) |
Note: A total of 20 cases
Biopsy/autopsy results of patients with pneumothorax secondary to GPA
| Biopsy site and pathology | Cases (n, %) |
|---|---|
| Lung (12 cases) | |
| Pulmonary nodules necrotizing granulomatous vasculitis | 6/12(50.0%) |
| bronchial pleural fistula | 2/12(16.7%) |
| Pleural necrotizing granulomatous vasculitis | 1/12(8.3%) |
| Subpleural blister and fibrosis, pulmonary fibrosis and elastic tissue hyperplasia | 1/12(8.3%) |
| Nose (necrotizing granulomatous vasculitis) | 8 |
| Skin (leukocytoclastic vasculitis) | 2 |
| Parotid (necrotizing granulomatous vasculitis) | 1 |
| Oral (necrotizing granulomatous vasculitis) | 1 |
Note: lung biopsy/autopsy in a total of 12 cases
Patients characteristics related to morality
| Clinical features | Death group( | Survival group | |
|---|---|---|---|
| ( | |||
| Male/Female(n) | 7(70.0%)/3(30.0%) | 8(80.0%)/4(40.0%) | 1.000 |
| Age (years) | 53 ± 12.9(33~70) | 40 ± 14.7(25~70) | 0.050 |
| Duration (weeks) | 19 ± 24.8(10~48) | 34 ± 69.2(0.83~216) | 0.547 |
| Extrapulmonary manifestations (n) | |||
| Fever | 3 (30.0%) | 7 (58.3%) | 0.231 |
| Skin lesions (purpura, gangrene, ulceration) | 3 (30.0%) | 3 (25.0%) | 1.000 |
| Ear (hearing loss, otitis media) | 2 (20.0%) | 4 (33.3%) | 0.646 |
| Nasal and sinus involvement | 5 (50.0%) | 7 (58.3%) | 1.000 |
| Oral ulceration | 4 (40.0%) | 1 (8.3%) | 0.135 |
| glomerulonephritis | 6 (60.0%) | 6 (50.0%) | 0.691 |
| Nervous system (facial paralysis, multiple mononeuropathy, etc.) | 3 (30.0%) | 1 (8.3%) | 0.293 |
| Arthralgia/arthritis | 4 (40.0%) | 4 (33.3%) | 1.000 |
| Parotid swelling and pain | 2 (20.0%) | 0 (0.0%) | 0.195 |
| ESR(mm/h) | 104 ± 26.7 | 82 ± 33.9 | 0.233 |
| Infection(n) | 6 (60.0%) | 3 (25.0%) | 0.192 |
| Corticosteroids and Immunosuppressants (n) | |||
| steroid pulse therapy | 1 (10.0%) | 4 (33.3%) | 0.323 |
| treatment interruption | 2/4(50.0%) | 0/8(0.0%) | 0.091 |
| Non-response to Pleural drainage (n) | 5/5 (100%) | 0/7 (0.0%) | 0.010 |
| Surgery(n) | 2 (20.0%) | 5 (41.7%) | 0.381 |
Note: 3 cases without prognostic information, n = 22 cases; ESR, erythrocyte sedimentation rate
Risk factors for pneumothorax secondary to GPA
| Risk factors |
|
|---|---|
| Active stage of Granulomatous vasculitis | 19/20(95.0%)a |
| Pulmonary nodules broke into the chest cavity | 15 |
| Pleural necrotizing granulomatous vasculitis | 1/12 (8.3%)b |
| Bronchial pleural fistula | 2/12 (16.7%)b |
| Lesions fibrosis with pleural cohesion | 1/12 (8.3%)b |
| Secondary infection in nodule cavity | 3 |
| Lesions fibrosis due to immunosuppressant | 1 |
| Delayed wound healing due to Glucocorticoid | 2 |
| Others | 1 |
aBased on symptoms, laboratory tests, pathology
bLung biopsy in 12 cases
Fig. 2The bilateral fixed nodules, cavitation, right hydropneumothorax in a patient with granulomatous vasculitis (GPA)